Endometrial cancer is the most common gynecologic cancer in the United States, comprising 6 % of diagnosed cancers and accounting for 3 % of all cancer deaths in women annually. Over 40,000 new cases of endometrial cancer are diagnosed in the USA every year [1]. On presentation, the vast majority are confined to the uterus. Treatment generally entails a hysterectomy and bilateral salpingo-oophorectomy, as well as peritoneal cytology with or without pelvic and/or para-aortic lymphadenectomy. Patients deemed to be at risk for recurrence may receive postoperative adjuvant radiation therapy and/or chemotherapy. The 5-year survival rate is 95 % for localized endometrial cancer and 83 % for all stages combined. Overall, the recurrence rate is approximately 15 %. The majority occur within the first 3 years [1].
